Aortic Stenosis and Heart Failure With Preserved Ejection Fraction: A Cautionary Tale of Common Partners.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pathophysiological and clinical literature without systematic search methodology
PubMed 42305086 · doi:10.1161/CIRCHEARTFAILURE.126.014249
What was done
This narrative review synthesized epidemiological, pathophysiological, and clinical literature regarding the overlap, shared cardiometabolic risk factors, and therapeutic considerations for coexisting aortic stenosis (AS) and heart failure with preserved ejection fraction (HFpEF).
What was found
The abstract reports no quantitative data or specific numerical metrics. Descriptively, the authors report that extra-valvular changes in AS (including left ventricular hypertrophy, diastolic dysfunction, and pulmonary vascular remodeling) closely mirror HFpEF. They report that residual HFpEF commonly accounts for ongoing heart failure burden after aortic valve replacement, mild AS is associated with worse outcomes in HFpEF, and HFpEF therapies such as sodium-glucose cotransporter 2 (SGLT2) inhibitors may provide benefit in selected AS patients.
Why it matters
Recognizing AS as a combined valvular and myocardial disease helps explain why valve replacement alone often fails to resolve heart failure symptoms and encourages testing HFpEF-directed medical therapies in patients with concomitant aortic stenosis.
Limits
The abstract provides no sample size, search protocol, quantitative outcome data, or effect sizes. As a narrative review, it offers descriptive clinical synthesis rather than new empirical data or systematic evidence grading.
Cited by
- supports Aortic valve stenosis narrows the valve orifice, forcing the lower heart chamber to push harder and causing ventricular hypertrophy.